<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040793</url>
  </required_header>
  <id_info>
    <org_study_id>1222.38</org_study_id>
    <secondary_id>2009-014416-35</secondary_id>
    <nct_id>NCT01040793</nct_id>
  </id_info>
  <brief_title>Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, 3-way Cross-over Study to Determine the Effect of Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 µg] and 10 µg [2 Actuations of 5 µg]) Delivered by the Respimat® Inhaler on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of
      treatment in patients with Chronic Obstructive Pulmonary Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Endurance Time After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Primary endpoint was endurance time during constant work rate ergometry to symptom limitation at 75% of maximal work capacity after 6 weeks of treatment. Mixed effects model on log10 transformation data. Adjusted means are back transformed to report as geometric means. Standard errors (SEs) are calculated using the delta method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Inspiratory Capacity at Isotime After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Isotime is defined as the endurance time of the constant work rate exercise test of shortest duration from Baseline visit, and Week 6 of each of the three treatment periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Borg Scale of Breathing Discomfort at Isotime After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Isotime is defined as the endurance time of the constant work rate exercise test of shortest duration from Baseline visit, and Week 6 of each of the three treatment periods.
Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Inspiratory Capacity at Pre-exercise After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Inspiratory Capacity at End of Exercise After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Borg Scale of Breathing Discomfort at Pre-exercise After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Borg Scale of Breathing Discomfort at End of Exercise After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Functional Residual Capacity 30 Minutes Pre-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured using body plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Functional Residual Capacity 1 Hour Post-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured using body plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Inspiratory Capacity 30 Minutes Pre-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured using body plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Inspiratory Capacity 1 Hour Post-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Total Lung Capacity 30 Minutes Pre-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured using body plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Total Lung Capacity 1 Hour Post-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured using body plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Forced Expiratory Volume in 1 Second, 30 Minutes Pre-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Forced Expiratory Volume in 1 Second, 1 Hour Post-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Forced Vital Capacity, 30 Minutes Pre-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Forced Vital Capacity, 1 Hour Post-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Peak Expiratory Flow Rate, 30 Minutes Pre-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Peak Expiratory Flow Rate, 1 Hour Post-dose After 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 43 in Blood Pressure</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change from Baseline to Day 43 in Blood Pressure with spirometry. Baseline is defined as mean of pre-treatment values at a given time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 43 in Pulse Rate</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change from Baseline to Day 43 in Pulse rate with spirometry. Baseline is defined as mean of pre-treatment values at a given time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Notable Changes in Heart Rate</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Number of Patients with notable changes in heart rate (HR). Notable HR increase defined as &gt;=25% increase and on-treatment HR &gt; 100 bpm; Notable HR decrease defined as &gt;=25% decrease and on-treatment HR &lt; 50 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Notable Increase in PR Intervals</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Number of Patients with notable increase in PR intervals. Notable PR interval increase defined as &gt;=25% increase and on-treatment PR interval &gt; 200 ms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Notable Increase in QRS Intervals</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Number of Patients with notable increase in QRS intervals. Notable QRS interval increase defined as &gt;=10% increase and on-treatment QRS interval &gt; 110 ms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olodaterol (BI 1744) placebo inhaled orally from the Respimat inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744)</intervention_name>
    <description>Comparison of low and high dose on exercise endurance time in COPD patients</description>
    <arm_group_label>Olodaterol (BI 1744) Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744)</intervention_name>
    <description>Comparison of low and high dose on exercise endurance time in COPD patients</description>
    <arm_group_label>Olodaterol (BI 1744) High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparison of low and high dose and placebo on exercise endurance time in COPD patients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI1744)</intervention_name>
    <description>Comparison of low and high dose on exercise endurance time in COPD patients</description>
    <arm_group_label>Olodaterol (BI 1744) Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744) placebo</intervention_name>
    <description>Placebo that represents olodaterol</description>
    <arm_group_label>Olodaterol (BI 1744) Low</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Signed informed consent prior to participation.

          2. Diagnosis of chronic obstructive pulmonary disease and post-bronchodilator FEV1(Forced
             Expiratory Volume in 1 sec) &lt;80% of predicted normal and post-bronchodilator
             FEV1(Forced Expiratory Volume in 1 sec)/FVC of &lt; 70% at Visit 1.

          3. Male or female between 40 and 75 years of age.

          4. Current or ex-smokers with smoking history of more than 10-pack years.

          5. Able to perform technically acceptable pulmonary function tests, multiple exercise
             tests and able to maintain records.

          6. Able to inhale medication in a competent manner from a metered-dose inhaler and
             Respimat inhaler.

        Exclusion criteria:

          1. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or
             urinalysis; all patients with an SGOT &gt;x2 ULN, SGPT &gt;x2 ULN, bilirubin &gt;x2 ULN or
             creatinine &gt;x2 ULN.

          2. Patients with a history of asthma and/or total blood eosinophil count of 600
             cells/mm3.

          3. Patients with thyrotoxicosis, paroxysmal tachycardia (&gt;100 beats per minute).

          4. Patients with a history of myocardial infarction within 1 year of screening visit,
             unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure
             within the past year, known active tuberculosis, a malignancy for which patient has
             undergone resection, radiation therapy or chemotherapy within last five years,
             life-threatening pulmonary obstruction, cystic fibrosis, clinically evident
             bronchiectasis, significant alcohol or drug abuse or contraindications to exercise.

          5. Patients who have undergone thoracotomy with pulmonary resection.

          6. Patients being treated with oral beta-adrenergics or oral corticosteroid medication at
             unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of
             the equivalent of 10 mg of prednisone per day or 20 mg every other day.

          7. Patients who regularly use daytime oxygen for more than one hour per day.

          8. Patients who have completed a pulmonary rehabilitation program in the six weeks prior
             to the screening visit or patients who are currently in a pulmonary rehabilitation
             program.

          9. Patients who have a limitation of exercise performance as a result of factors other
             than fatigue or exertional dyspnea.

         10. Pregnant or nursing women.

         11. Women of childbearing potential not using two effective methods of birth control (one
             barrier and one non-barrier).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.38.4380 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hallein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.4381 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.1082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.1081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.1083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.1080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.4980 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.4983 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.4984 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.4981 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.4986 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.4985 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.7080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.7081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.38.7082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2009</study_first_submitted>
  <study_first_submitted_qc>December 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2009</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>July 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2014</results_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a randomised, double-blind, placebo-controlled, 3-way crossover trial. The duration of each treatment period was 6 weeks with a 14 day washout period between treatments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo / Olo 5mcg / Olo 10mcg</title>
          <description>Patients were administered placebo in the first period, Olodaterol 5 mcg qd in the second period and Olodaterol 10 mcg qd in the third period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P2">
          <title>Placebo / Olo 10mcg / Olo 5mcg</title>
          <description>Patients were administered placebo in the first period, Olodaterol 10 mcg qd in the second period and Olodaterol 5 mcg qd in the third period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P3">
          <title>Olo 5mcg/ Placebo / Olo 10mcg</title>
          <description>Patients were administered Olodaterol 5 mcg qd in the first period, placebo in the second period and Olodaterol 10 mcg qd in the third period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P4">
          <title>Olo 5mcg / Olo 10mcg / Placebo</title>
          <description>Patients were administered Olodaterol 5 mcg qd in the first period, Olodaterol 10 mcg qd in the second period and placebo in the third period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P5">
          <title>Olo 10mcg / Placebo / Olo 5mcg</title>
          <description>Patients were administered Olodaterol 10 mcg qd in the first period, placebo in the second period and Olodaterol 5 mcg qd in the third period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P6">
          <title>Olo 10mcg / Olo 5mcg / Placebo</title>
          <description>Patients were administered Olodaterol 10 mcg qd in the first period, Olodaterol 5 mcg qd in the second period and placebo in the third period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">Entered and treated</participants>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons not listed above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Total number of patients treated in the study. This was a randomised, double-blind, placebo-controlled, 3-way crossover trial. 151 patients were assigned randomly to one of 3 treatment sequences in which they received each of 3 treatments. The duration of each treatment period was 6 weeks with a 14 day washout period between treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Endurance Time After 6 Weeks</title>
        <description>Primary endpoint was endurance time during constant work rate ergometry to symptom limitation at 75% of maximal work capacity after 6 weeks of treatment. Mixed effects model on log10 transformation data. Adjusted means are back transformed to report as geometric means. Standard errors (SEs) are calculated using the delta method.</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Endurance Time After 6 Weeks</title>
          <description>Primary endpoint was endurance time during constant work rate ergometry to symptom limitation at 75% of maximal work capacity after 6 weeks of treatment. Mixed effects model on log10 transformation data. Adjusted means are back transformed to report as geometric means. Standard errors (SEs) are calculated using the delta method.</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint.</population>
          <units>seconds</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.33" spread="12.069"/>
                    <measurement group_id="O2" value="396.31" spread="13.680"/>
                    <measurement group_id="O3" value="391.45" spread="13.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline endurance time and period as fixed and patient as random effect. Means, CI back-transformed.</method_desc>
            <param_type>Ratio to placebo</param_type>
            <param_value>1.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.043</ci_lower_limit>
            <ci_upper_limit>1.199</ci_upper_limit>
            <estimate_desc>Olo 5 mcg divided by Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline endurance time and period as fixed and patient as random effect. Means, CI back-transformed.</method_desc>
            <param_type>Ratio to placebo</param_type>
            <param_value>1.105</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.030</ci_lower_limit>
            <ci_upper_limit>1.184</ci_upper_limit>
            <estimate_desc>Olo 10 mcg divided by Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Inspiratory Capacity at Isotime After 6 Weeks</title>
        <description>Isotime is defined as the endurance time of the constant work rate exercise test of shortest duration from Baseline visit, and Week 6 of each of the three treatment periods.</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Inspiratory Capacity at Isotime After 6 Weeks</title>
          <description>Isotime is defined as the endurance time of the constant work rate exercise test of shortest duration from Baseline visit, and Week 6 of each of the three treatment periods.</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.162" spread="0.039"/>
                    <measurement group_id="O2" value="2.246" spread="0.039"/>
                    <measurement group_id="O3" value="2.328" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0155</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Borg Scale of Breathing Discomfort at Isotime After 6 Weeks</title>
        <description>Isotime is defined as the endurance time of the constant work rate exercise test of shortest duration from Baseline visit, and Week 6 of each of the three treatment periods.
Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Borg Scale of Breathing Discomfort at Isotime After 6 Weeks</title>
          <description>Isotime is defined as the endurance time of the constant work rate exercise test of shortest duration from Baseline visit, and Week 6 of each of the three treatment periods.
Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.585" spread="0.177"/>
                    <measurement group_id="O2" value="5.250" spread="0.180"/>
                    <measurement group_id="O3" value="5.520" spread="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1176</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.366</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.214</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.757</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7591</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.066</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.214</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.486</ci_lower_limit>
            <ci_upper_limit>0.355</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Inspiratory Capacity at Pre-exercise After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Inspiratory Capacity at Pre-exercise After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.273" spread="0.036"/>
                    <measurement group_id="O2" value="2.437" spread="0.036"/>
                    <measurement group_id="O3" value="2.468" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.164</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.195</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.125</ci_lower_limit>
            <ci_upper_limit>0.265</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Inspiratory Capacity at End of Exercise After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Inspiratory Capacity at End of Exercise After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.158" spread="0.039"/>
                    <measurement group_id="O2" value="2.236" spread="0.040"/>
                    <measurement group_id="O3" value="2.330" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0245</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.105</ci_lower_limit>
            <ci_upper_limit>0.240</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Borg Scale of Breathing Discomfort at Pre-exercise After 6 Weeks</title>
        <description>Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Borg Scale of Breathing Discomfort at Pre-exercise After 6 Weeks</title>
          <description>Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.389" spread="0.062"/>
                    <measurement group_id="O2" value="0.315" spread="0.063"/>
                    <measurement group_id="O3" value="0.364" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2897</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.074</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.070</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.211</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7199</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.025</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.162</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Borg Scale of Breathing Discomfort at End of Exercise After 6 Weeks</title>
        <description>Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Borg Scale of Breathing Discomfort at End of Exercise After 6 Weeks</title>
          <description>Borg scale rates discomfort with breathing at rest, during exercise and at end-exercise on a scale from 0=Nothing at all to 10=Maximal discomfort.</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.010" spread="0.129"/>
                    <measurement group_id="O2" value="7.101" spread="0.131"/>
                    <measurement group_id="O3" value="7.351" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5313</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.146</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.196</ci_lower_limit>
            <ci_upper_limit>0.379</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0198</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.341</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.146</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.628</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Functional Residual Capacity 30 Minutes Pre-dose After 6 Weeks</title>
        <description>Measured using body plethysmography</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Functional Residual Capacity 30 Minutes Pre-dose After 6 Weeks</title>
          <description>Measured using body plethysmography</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.842" spread="0.062"/>
                    <measurement group_id="O2" value="4.757" spread="0.063"/>
                    <measurement group_id="O3" value="4.723" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1048</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.190</ci_lower_limit>
            <ci_upper_limit>0.018</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0246</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.120</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.224</ci_lower_limit>
            <ci_upper_limit>-0.015</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Functional Residual Capacity 1 Hour Post-dose After 6 Weeks</title>
        <description>Measured using body plethysmography</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Functional Residual Capacity 1 Hour Post-dose After 6 Weeks</title>
          <description>Measured using body plethysmography</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.770" spread="0.065"/>
                    <measurement group_id="O2" value="4.557" spread="0.065"/>
                    <measurement group_id="O3" value="4.583" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.213</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.318</ci_lower_limit>
            <ci_upper_limit>-0.108</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.187</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.293</ci_lower_limit>
            <ci_upper_limit>-0.082</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Inspiratory Capacity 30 Minutes Pre-dose After 6 Weeks</title>
        <description>Measured using body plethysmography</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Inspiratory Capacity 30 Minutes Pre-dose After 6 Weeks</title>
          <description>Measured using body plethysmography</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.463" spread="0.041"/>
                    <measurement group_id="O2" value="2.613" spread="0.041"/>
                    <measurement group_id="O3" value="2.618" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.071</ci_lower_limit>
            <ci_upper_limit>0.228</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.154</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.076</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Inspiratory Capacity 1 Hour Post-dose After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Inspiratory Capacity 1 Hour Post-dose After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.493" spread="0.040"/>
                    <measurement group_id="O2" value="2.725" spread="0.040"/>
                    <measurement group_id="O3" value="2.696" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.232</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.162</ci_lower_limit>
            <ci_upper_limit>0.303</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.203</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.133</ci_lower_limit>
            <ci_upper_limit>0.273</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Total Lung Capacity 30 Minutes Pre-dose After 6 Weeks</title>
        <description>Measured using body plethysmography</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Total Lung Capacity 30 Minutes Pre-dose After 6 Weeks</title>
          <description>Measured using body plethysmography</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.311" spread="0.067"/>
                    <measurement group_id="O2" value="7.368" spread="0.067"/>
                    <measurement group_id="O3" value="7.340" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3109</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.057</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6080</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.081</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Total Lung Capacity 1 Hour Post-dose After 6 Weeks</title>
        <description>Measured using body plethysmography</description>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Total Lung Capacity 1 Hour Post-dose After 6 Weeks</title>
          <description>Measured using body plethysmography</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.262" spread="0.069"/>
                    <measurement group_id="O2" value="7.285" spread="0.069"/>
                    <measurement group_id="O3" value="7.272" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6809</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.087</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8580</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.100</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Forced Expiratory Volume in 1 Second, 30 Minutes Pre-dose After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Forced Expiratory Volume in 1 Second, 30 Minutes Pre-dose After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.520" spread="0.024"/>
                    <measurement group_id="O2" value="1.630" spread="0.025"/>
                    <measurement group_id="O3" value="1.630" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Forced Expiratory Volume in 1 Second, 1 Hour Post-dose After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Forced Expiratory Volume in 1 Second, 1 Hour Post-dose After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.577" spread="0.026"/>
                    <measurement group_id="O2" value="1.768" spread="0.026"/>
                    <measurement group_id="O3" value="1.771" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.195</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.153</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Forced Vital Capacity, 30 Minutes Pre-dose After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Forced Vital Capacity, 30 Minutes Pre-dose After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.103" spread="0.039"/>
                    <measurement group_id="O2" value="3.222" spread="0.040"/>
                    <measurement group_id="O3" value="3.222" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Forced Vital Capacity, 1 Hour Post-dose After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Forced Vital Capacity, 1 Hour Post-dose After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.144" spread="0.039"/>
                    <measurement group_id="O2" value="3.409" spread="0.040"/>
                    <measurement group_id="O3" value="3.425" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.196</ci_lower_limit>
            <ci_upper_limit>0.333</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.281</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.212</ci_lower_limit>
            <ci_upper_limit>0.350</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Peak Expiratory Flow Rate, 30 Minutes Pre-dose After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Peak Expiratory Flow Rate, 30 Minutes Pre-dose After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters/second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.258" spread="0.081"/>
                    <measurement group_id="O2" value="4.539" spread="0.081"/>
                    <measurement group_id="O3" value="4.549" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.281</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.405</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.291</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.416</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Peak Expiratory Flow Rate, 1 Hour Post-dose After 6 Weeks</title>
        <time_frame>6 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Peak Expiratory Flow Rate, 1 Hour Post-dose After 6 Weeks</title>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and any evaluable post-dose data for the primary endpoint. Only patients who have baseline and at least one post-baseline measurement available were included in the analysis.</population>
          <units>liters/second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.324" spread="0.085"/>
                    <measurement group_id="O2" value="4.904" spread="0.085"/>
                    <measurement group_id="O3" value="4.876" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.580</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.070</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.441</ci_lower_limit>
            <ci_upper_limit>0.719</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects repeated measures with treatment, baseline and period as fixed and patient as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.552</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.071</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.412</ci_lower_limit>
            <ci_upper_limit>0.691</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 43 in Blood Pressure</title>
        <description>Change from Baseline to Day 43 in Blood Pressure with spirometry. Baseline is defined as mean of pre-treatment values at a given time point.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Treated set. Statistics only include patients with both a baseline and a post dose value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 43 in Blood Pressure</title>
          <description>Change from Baseline to Day 43 in Blood Pressure with spirometry. Baseline is defined as mean of pre-treatment values at a given time point.</description>
          <population>Treated set. Statistics only include patients with both a baseline and a post dose value.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="15.87"/>
                    <measurement group_id="O2" value="-1.5" spread="15.47"/>
                    <measurement group_id="O3" value="-1.4" spread="15.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="8.95"/>
                    <measurement group_id="O2" value="-1.8" spread="8.35"/>
                    <measurement group_id="O3" value="-2.2" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 43 in Pulse Rate</title>
        <description>Change from Baseline to Day 43 in Pulse rate with spirometry. Baseline is defined as mean of pre-treatment values at a given time point.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Treated set. Statistics only include patients with both a baseline and a post dose value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 43 in Pulse Rate</title>
          <description>Change from Baseline to Day 43 in Pulse rate with spirometry. Baseline is defined as mean of pre-treatment values at a given time point.</description>
          <population>Treated set. Statistics only include patients with both a baseline and a post dose value.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="12.33"/>
                    <measurement group_id="O2" value="-1.8" spread="11.69"/>
                    <measurement group_id="O3" value="-1.6" spread="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Notable Changes in Heart Rate</title>
        <description>Number of Patients with notable changes in heart rate (HR). Notable HR increase defined as &gt;=25% increase and on-treatment HR &gt; 100 bpm; Notable HR decrease defined as &gt;=25% decrease and on-treatment HR &lt; 50 bpm.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Notable Changes in Heart Rate</title>
          <description>Number of Patients with notable changes in heart rate (HR). Notable HR increase defined as &gt;=25% increase and on-treatment HR &gt; 100 bpm; Notable HR decrease defined as &gt;=25% decrease and on-treatment HR &lt; 50 bpm.</description>
          <population>Treated set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 min pre-dose: increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min pre-dose: decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min pre-dose: no notable change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                    <measurement group_id="O2" value="97.9"/>
                    <measurement group_id="O3" value="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min post-dose: increase (N=147,142,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min post-dose: decrease (N=147,142,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min post-dose: no notable change(N=147,142,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                    <measurement group_id="O2" value="95.8"/>
                    <measurement group_id="O3" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Notable Increase in PR Intervals</title>
        <description>Number of Patients with notable increase in PR intervals. Notable PR interval increase defined as &gt;=25% increase and on-treatment PR interval &gt; 200 ms.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Notable Increase in PR Intervals</title>
          <description>Number of Patients with notable increase in PR intervals. Notable PR interval increase defined as &gt;=25% increase and on-treatment PR interval &gt; 200 ms.</description>
          <population>Treated set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 min pre-dose: increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min pre-dose: no increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min post-dose: increase (N=147, 142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min post-dose: no increase (N=147, 142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Notable Increase in QRS Intervals</title>
        <description>Number of Patients with notable increase in QRS intervals. Notable QRS interval increase defined as &gt;=10% increase and on-treatment QRS interval &gt; 110 ms.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Notable Increase in QRS Intervals</title>
          <description>Number of Patients with notable increase in QRS intervals. Notable QRS interval increase defined as &gt;=10% increase and on-treatment QRS interval &gt; 110 ms.</description>
          <population>Treated set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 min pre-dose: increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min pre-dose: no increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                    <measurement group_id="O2" value="99.3"/>
                    <measurement group_id="O3" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min post-dose: increase (N=147, 142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min post-dose: no increase (N=147, 142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                    <measurement group_id="O2" value="99.3"/>
                    <measurement group_id="O3" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Olo 5 mcg</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olo 10 mcg</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

